GGB Awards Return To Frankfurt In 2025

Entries Are Now Open Ahead Of 29 October Awards Ceremony In Germany

The Global Generics & Biosimilars Awards is taking place in Frankfurt this October, with the event returning to Germany in its twelfth year for an even bigger and better awards ceremony that will recognize the most outstanding achievements across the generics, biosimilars and value added medicines industries. Entries are now open and you can also book tickets to attend, both of which are free of charge.

The GGB Awards 2025 will take place on 29 October in Frankfurt (Shutterstock)

Frankfurt is the venue for the Global Generics & Biosimilars Awards 2025, with entries now open for our annual celebration of the off-patent industry’s leading accomplishments, ahead of a prizegiving ceremony that will take place on Wednesday 29 October, during CPhI Worldwide week.

Now in their twelfth year, the awards – which are free to enter and attend, with our awards ceremony taking place at the Radisson Blu Hotel, Frankfurt – celebrate the greatest achievements across the generics, biosimilars and value added medicines industries.

Entries are open until Friday 1 August 2025 and can cover any activities undertaken between 1 August 2024 and 31 July 2025. As in previous years, our categories include:

  • Company of the Year
  • Regional Companies of the Year – Americas, APAC and EMEA
  • Acquisition of the Year
  • Leader of the Year
  • Value Added Medicine Initiative of the Year
  • Business Development of the Year
  • API Supplier of the Year
  • Biosimilar Initiative of the Year
  • Regulatory Achievement of the Year
  • Corporate Social Responsibility (CSR) Initiative of the Year
  • Industry Partner of the Year
  • Campaign of the Year

Our CSR Initiative of the Year award will once again be supported by longtime associate International Health Partners.

“We can’t wait to be back in Frankfurt, in an impressive new venue, to celebrate the greatest achievements seen this year by the global generics, biosimilars and value added medicines industry,” commented Dave Wallace, executive editor of Generics Bulletin.

“With the off-patent industry playing an increasingly important role in contributing valuable treatments to healthcare systems worldwide at affordable prices, while also broadening access to essential medicines, we’re proud to be shining the spotlight on the companies and individuals that are leading these achievements.”

The Global Generics & Biosimilars Awards prides itself on its independence, with winners chosen solely on merit and acknowledged as the most deserving of recognition for their unique achievements.

All submissions are reviewed by an independent panel of expert judges, who have been selected on the basis of their industry knowledge and impartiality.

For a full list of the awards categories, submissions criteria, how to attend and other information, go here.

To enquire about sponsorship opportunities, please e-mail George.Wilkins@citeline.com

And to register interest in attending the Global Generics & Biosimilars Awards 2025, to receive the latest updates and for any further details, please e-mail Natalia.Kay@citeline.com

More from Generics

US FDA Shows Support For Generic Drug User Fee Goals Amid Cutbacks

 

The FDA struck an upbeat tone during its annual Generic Drugs Forum despite an unprecedented period of cutbacks and disruptions and reiterated a desire to continue meeting user fee goals.

OGD’s Policy Office Cut To Have ‘Profound’ Impact On New Generic Approvals, Warns Former FDA Head Gottlieb

 

The elimination of the policy division at the Office of Generic Drugs, tariffs, the Section 232 investigation, and a new executive order to promote lower drug prices seem to both cause and purport to solve the same problem: supply chain disruption.

Sunshine Becomes Latest To Compete On Everolimus In Canada

 
• By 

Sunshine Biopharma is continuing to roll out generic launches in Canada, with its latest product challenging Afinitor and other everolimus rivals in the market.

Regulatory Recap: UK To Capture £1bn Savings With Framework For Best-Value Biologics

 

Generics Bulletin reviews global regulatory developments across the world.

More from Value Added Medicines

GGB Awards Return To Frankfurt In 2025

 
• By 

The Global Generics & Biosimilars Awards is taking place in Frankfurt this October, with the event returning to Germany in its twelfth year for an even bigger and better awards ceremony that will recognize the most outstanding achievements across the generics, biosimilars and value added medicines industries. Entries are now open and you can also book tickets to attend, both of which are free of charge.

With New Data, Lipella Plots 2025 Milestones For Oral Rinse Tacrolimus

 
• By 

Reformulation specialist Lipella has an eye on numerous milestones for its proposed oral rinse liposomal formulation of tacrolimus, including the submission of a Phase IIb clinical trial investigational new drug application.

Adial Is Filling The Gap In Alcohol Use Disorder Treatment With Repurposed Drug

 

Adial Pharmaceuticals’ CEO Cary Claiborne discussed with Generics Bulletin how repurposing antinausea drug ondansetron and genetically targeting patients with specific biomarkers can address the unmet need in the current treatment of addiction.